record initialized not assigned to examiner
on 16 Dec 2023
Last Applicant/ Owned by
SUITE 1900
CINCINNATI
OH
45202
Serial Number
98267927 filed on 13th Nov 2023
Registration Number
N/A
Correspondent Address
DANIELLE COHEN, ESQ.
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Pharmaceuticals; pharmaceuticals, namely, small molecules, biopharmaceuticals, cellular therapies, gene therapies, vaccines, CRISPR-Cas9 derived, CAR T-Cell derived, N - 1 personalized drug therapies, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, monoclonal antibodies, bi-specific antibodies, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics; diaRead More
Pharmaceuticals; pharmaceuticals, namely, small molecules, biopharmaceuticals, cellular therapies, gene therapies, vaccines, CRISPR-Cas9 derived, CAR T-Cell derived, N - 1 personalized drug therapies, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, monoclonal antibodies, bi-specific antibodies, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics; diagnostics; diagnostics, namely, in-vitro, in-vivo, and cell-based assays, cell culture processes, laboratory-developed tests (LDTs), cell-based imagining, genomics, gene-based expression assays, proteomics, protein-based expression assays, immunohistochemistry (IHC), drug sensitivity and treatment diagnostics, diagnostic algorithms and decision-making computational software to support screening, diagnosing, monitoring and treatment modalities; medical devices; medical devices, namely, devices that deliver therapeutic drugs of various types, namely, small molecules, biopharmaceuticals, cellular therapies, gene therapies, vaccines, CRISPR-Cas9 derived, CAR T-Cell derived, N - 1 personalized drug therapies, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, monoclonal antibodies, bi-specific antibodies, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics, into the human body utilizing both in-vivo and in-vitro (gene or cellular therapies) methods for personalized medical therapeutics; Computational, Software, and decision systems; computational, software, and decision systems, namely, products and services for clinical and after-regulatory approval of both therapeutics and diagnostics (theranostics) that support and maintain pre-clinical trials, clinical trials and assessments of patient's tumors in their staging and treatment; Biobanking and Research; biobanking and research, namely, acquisition, processing, analysis, and storage of human and animal specimens in a biobanking facility that is used for personalized medicine with patient treatment (therapeutics and diagnostics). Digital Pathology and other imaging and cellular systems for the characterization of human and animal tumors
No 98267927
No Service/Collective Mark
No 17974.036
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
24th Jan 2024 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
16th Dec 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |